Abstract
While Gene Therapies (GTs) represent transformative therapies for patients, they require a complex manufacturing and delivery process. This, coupled with small target populations, is associated with high price expectations. However, benefits of GTs are frequently only realized in the long-term, posing affordability challenges for payers. To manage this, payers have entered into risk-sharing agreements and innovative payment models with GT developers. The aim of this study was to review managed entry agreements (MEAs) and innovative payment models that have been put in place for GTs in the G7 countries and Canada to identify trends.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
